[
  {
    "ts": null,
    "headline": "Novo Nordisk shares plunge after profit warning over US weight-loss copycats",
    "summary": "Novo Nordisk’s shares plunged more than a fifth on Tuesday, wiping more than €60bn from its value, after it slashed sales and profit forecasts...",
    "url": "https://finnhub.io/api/news?id=478d7cc16776c84fa83037b9704920dded7778828bd825d3407a33dc447ef64e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753830788,
      "headline": "Novo Nordisk shares plunge after profit warning over US weight-loss copycats",
      "id": 136129641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk’s shares plunged more than a fifth on Tuesday, wiping more than €60bn from its value, after it slashed sales and profit forecasts...",
      "url": "https://finnhub.io/api/news?id=478d7cc16776c84fa83037b9704920dded7778828bd825d3407a33dc447ef64e"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Was Looking Sickly Today",
    "summary": "It seemed the market overreacted to discouraging news from one of the company's rivals.",
    "url": "https://finnhub.io/api/news?id=d98a2894aabb8c95f7a4ee3bba5b58419d7257921a596de479f47fb6b422d1ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753826815,
      "headline": "Why Eli Lilly Stock Was Looking Sickly Today",
      "id": 136129642,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It seemed the market overreacted to discouraging news from one of the company's rivals.",
      "url": "https://finnhub.io/api/news?id=d98a2894aabb8c95f7a4ee3bba5b58419d7257921a596de479f47fb6b422d1ef"
    }
  },
  {
    "ts": null,
    "headline": "LipoVive Releases Ingredient Report Comparing Natural GLP-1 Support to Synthetic Drugs Like Mounjaro",
    "summary": "A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription MedicationsNew York, July 29, 2025 (GLOBE NEWSWIRE) -- Disclaimer: The information provided in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a licensed healthcare provider before beginning any new supplement or wellness routine. Trademark Disclaimer: Mounjaro® is a registered",
    "url": "https://finnhub.io/api/news?id=4677d199a5aaa94860391383a9d95e8f4f740dbdd11f31ac6049822b2bd1c4ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753825920,
      "headline": "LipoVive Releases Ingredient Report Comparing Natural GLP-1 Support to Synthetic Drugs Like Mounjaro",
      "id": 136129643,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription MedicationsNew York, July 29, 2025 (GLOBE NEWSWIRE) -- Disclaimer: The information provided in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a licensed healthcare provider before beginning any new supplement or wellness routine. Trademark Disclaimer: Mounjaro® is a registered",
      "url": "https://finnhub.io/api/news?id=4677d199a5aaa94860391383a9d95e8f4f740dbdd11f31ac6049822b2bd1c4ce"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Declines More Than Market: Some Information for Investors",
    "summary": "Eli Lilly (LLY) reached $762.95 at the closing of the latest trading day, reflecting a -5.59% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=41cf4a8e76de290acba48c859d9a6b8a2c46c1185246bd2b48aa0c46bfb5dba7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753825502,
      "headline": "Eli Lilly (LLY) Declines More Than Market: Some Information for Investors",
      "id": 136129644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) reached $762.95 at the closing of the latest trading day, reflecting a -5.59% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=41cf4a8e76de290acba48c859d9a6b8a2c46c1185246bd2b48aa0c46bfb5dba7"
    }
  },
  {
    "ts": null,
    "headline": "Lilly set for strong quarter after Novo profit warning",
    "summary": "(Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook and updates on an experimental obesity drug to gauge the U.S. drugmaker's longer-term health.  Lilly's weight-loss drug Zepbound leads the U.S. market and has faced less competition from cheaper copies made by compounding pharmacies, giving it an edge, they said, after investors wiped $70 billion from Novo's market value.  Novo, which sells the obesity drug Wegovy and related diabetes medicine Ozempic, on Tuesday issued a profit warning, citing lower U.S. growth expectations and competition including from compounded versions.",
    "url": "https://finnhub.io/api/news?id=fd7a009ce6a5b955c106560127251aad0133406c6d7144ee292b9fcfa84b2e10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753818579,
      "headline": "Lilly set for strong quarter after Novo profit warning",
      "id": 136129645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook and updates on an experimental obesity drug to gauge the U.S. drugmaker's longer-term health.  Lilly's weight-loss drug Zepbound leads the U.S. market and has faced less competition from cheaper copies made by compounding pharmacies, giving it an edge, they said, after investors wiped $70 billion from Novo's market value.  Novo, which sells the obesity drug Wegovy and related diabetes medicine Ozempic, on Tuesday issued a profit warning, citing lower U.S. growth expectations and competition including from compounded versions.",
      "url": "https://finnhub.io/api/news?id=fd7a009ce6a5b955c106560127251aad0133406c6d7144ee292b9fcfa84b2e10"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) Stock Is Falling Today",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the weight-loss drug market, Novo Nordisk, lowered its sales and profit growth forecasts for 2025. The lowered guidance from the Danish pharmaceutical giant cast a shadow over the high-growth weight-loss drug sector. This was the second time this year Novo Nordisk had reduced its outlook, which amplified investor concerns about the market's future performance. Compounding the",
    "url": "https://finnhub.io/api/news?id=e0f47ea9ec553d05d05a9454b77158363bede976c769f203a7ed1ad51fa132f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753813575,
      "headline": "Why Eli Lilly (LLY) Stock Is Falling Today",
      "id": 136129646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the weight-loss drug market, Novo Nordisk, lowered its sales and profit growth forecasts for 2025. The lowered guidance from the Danish pharmaceutical giant cast a shadow over the high-growth weight-loss drug sector. This was the second time this year Novo Nordisk had reduced its outlook, which amplified investor concerns about the market's future performance. Compounding the",
      "url": "https://finnhub.io/api/news?id=e0f47ea9ec553d05d05a9454b77158363bede976c769f203a7ed1ad51fa132f4"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Inc Sees Significant Reduction in Eaton Vance Worldwide Health ...",
    "summary": "Insights from the Fund's Second Quarter 2025 N-PORT Filing",
    "url": "https://finnhub.io/api/news?id=77599de5bfe3154d9a6a35a14726c7f2bda9c9483fcea61a6d8c3262b679890a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753812043,
      "headline": "Thermo Fisher Scientific Inc Sees Significant Reduction in Eaton Vance Worldwide Health ...",
      "id": 136129647,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Insights from the Fund's Second Quarter 2025 N-PORT Filing",
      "url": "https://finnhub.io/api/news?id=77599de5bfe3154d9a6a35a14726c7f2bda9c9483fcea61a6d8c3262b679890a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Announces Positive Results For Jaypirca In Phase 3 Trial",
    "summary": "Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia. The company's 6% share price increase over the past week may have been influenced by investor optimism surrounding these findings, aligning with general market trends which saw the S&P 500 and Nasdaq reach new highs. While broader market dynamics favor strong corporate earnings and positive...",
    "url": "https://finnhub.io/api/news?id=2f87e90218bfe2679112897fc1ed1d9a238461a711c95c69e93971e8fbada2ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753810343,
      "headline": "Eli Lilly (LLY) Announces Positive Results For Jaypirca In Phase 3 Trial",
      "id": 136129648,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia. The company's 6% share price increase over the past week may have been influenced by investor optimism surrounding these findings, aligning with general market trends which saw the S&P 500 and Nasdaq reach new highs. While broader market dynamics favor strong corporate earnings and positive...",
      "url": "https://finnhub.io/api/news?id=2f87e90218bfe2679112897fc1ed1d9a238461a711c95c69e93971e8fbada2ec"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Shares Plummet as Competition Weighs on Sales",
    "summary": "The pharma giant cut its guidance and named a new CEO, hoping to revive growth. Its stock fell as much as 30%, wiping almost $93 billion from its market value.",
    "url": "https://finnhub.io/api/news?id=8b601bab97de7062a70383cc85f5bd6abbc41902e6acac6a0a274ce6667a1231",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753796640,
      "headline": "Novo Nordisk Shares Plummet as Competition Weighs on Sales",
      "id": 136118159,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharma giant cut its guidance and named a new CEO, hoping to revive growth. Its stock fell as much as 30%, wiping almost $93 billion from its market value.",
      "url": "https://finnhub.io/api/news?id=8b601bab97de7062a70383cc85f5bd6abbc41902e6acac6a0a274ce6667a1231"
    }
  },
  {
    "ts": null,
    "headline": "The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%.",
    "summary": "The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and Ozempic in the U.S. market.",
    "url": "https://finnhub.io/api/news?id=079d92b4d54b010cdec37189f84a3cde16e0918798017ffdb5211a04224a0ddc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753808100,
      "headline": "The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%.",
      "id": 136120693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and Ozempic in the U.S. market.",
      "url": "https://finnhub.io/api/news?id=079d92b4d54b010cdec37189f84a3cde16e0918798017ffdb5211a04224a0ddc"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia's TSMC order, Eli Lilly & Novo Nordisk sink, JPMorgan & Apple card",
    "summary": "Julie Hyman outlines some of the top market stories as part of today's Market Minute. Nvidia (NVDA) reportedly placed an order for 300,000 H20 chipsets with Taiwan Semiconductor Manufacturing Company (TSM) in preparation to sell in China, according to reporting from Reuters. Eli Lilly (LLY) shares fall as Novo Nordisk (NVO) stock plummets amid fears about the weight-loss drug boom slowing. JPMorgan (JPM) is reportedly in talks with Apple (AAPL) to take over the iPhone maker's credit card business from Goldman Sachs (GS), according to a report from The Wall Street Journal. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=353a8754978f3e8d836db02110035f00978e372529a1be2f9ef61eac6abaa409",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753805659,
      "headline": "Nvidia's TSMC order, Eli Lilly & Novo Nordisk sink, JPMorgan & Apple card",
      "id": 136118961,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Julie Hyman outlines some of the top market stories as part of today's Market Minute. Nvidia (NVDA) reportedly placed an order for 300,000 H20 chipsets with Taiwan Semiconductor Manufacturing Company (TSM) in preparation to sell in China, according to reporting from Reuters. Eli Lilly (LLY) shares fall as Novo Nordisk (NVO) stock plummets amid fears about the weight-loss drug boom slowing. JPMorgan (JPM) is reportedly in talks with Apple (AAPL) to take over the iPhone maker's credit card business from Goldman Sachs (GS), according to a report from The Wall Street Journal. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=353a8754978f3e8d836db02110035f00978e372529a1be2f9ef61eac6abaa409"
    }
  },
  {
    "ts": null,
    "headline": "Novo Lifer Takes Job of Reviving Europe’s Weight-Loss Superstar",
    "summary": "(Bloomberg) -- Maziar Mike Doustdar spent more than three decades quietly climbing the ranks of Novo Nordisk A/S, from office clerk through logistics and marketing roles to head of international operations. Now the relatively unknown insider is moving into the spotlight with a daunting task: revive a once high-flying drugmaker from a steep descent that’s wiped out two-thirds of its value in the past year.Most Read from BloombergBudapest’s Most Historic Site Gets a Controversial RebuildSan Franci",
    "url": "https://finnhub.io/api/news?id=0072b7062438170736aa99abb6862fec763d845ac9151158ac6b7752a432a0c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753805288,
      "headline": "Novo Lifer Takes Job of Reviving Europe’s Weight-Loss Superstar",
      "id": 136119115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Maziar Mike Doustdar spent more than three decades quietly climbing the ranks of Novo Nordisk A/S, from office clerk through logistics and marketing roles to head of international operations. Now the relatively unknown insider is moving into the spotlight with a daunting task: revive a once high-flying drugmaker from a steep descent that’s wiped out two-thirds of its value in the past year.Most Read from BloombergBudapest’s Most Historic Site Gets a Controversial RebuildSan Franci",
      "url": "https://finnhub.io/api/news?id=0072b7062438170736aa99abb6862fec763d845ac9151158ac6b7752a432a0c8"
    }
  },
  {
    "ts": null,
    "headline": "Novo's new CEO faces sceptical investors with Wegovy US sales in focus",
    "summary": "LONDON (Reuters) -Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales growth and sliding share price.  \"The company needs to address recent market challenges with speed and ambition,\" Novo Nordisk Chair Helge Lund said in a statement on Tuesday.  Investors aren't so sure, worried that Doustdar's lack of U.S. experience will hinder his ability to turn things around in Novo's top market and take the battle to tough U.S. rival Eli Lilly.",
    "url": "https://finnhub.io/api/news?id=7bb2546fbf08d2c4334a9d909e16b9f95ac49a0cef1eaf7b58fb42ada73bc8e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753804519,
      "headline": "Novo's new CEO faces sceptical investors with Wegovy US sales in focus",
      "id": 136119116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LONDON (Reuters) -Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales growth and sliding share price.  \"The company needs to address recent market challenges with speed and ambition,\" Novo Nordisk Chair Helge Lund said in a statement on Tuesday.  Investors aren't so sure, worried that Doustdar's lack of U.S. experience will hinder his ability to turn things around in Novo's top market and take the battle to tough U.S. rival Eli Lilly.",
      "url": "https://finnhub.io/api/news?id=7bb2546fbf08d2c4334a9d909e16b9f95ac49a0cef1eaf7b58fb42ada73bc8e1"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook",
    "summary": "Novo Nordisk cut its 2025 guidance and outgoing CEO blames the compounding market for it.",
    "url": "https://finnhub.io/api/news?id=6f73796302ba9ddb1188584c5c543966655926d122ab9a813988d5722f57ccf0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753804230,
      "headline": "Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook",
      "id": 136119117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk cut its 2025 guidance and outgoing CEO blames the compounding market for it.",
      "url": "https://finnhub.io/api/news?id=6f73796302ba9ddb1188584c5c543966655926d122ab9a813988d5722f57ccf0"
    }
  },
  {
    "ts": null,
    "headline": "INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales",
    "summary": "Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.",
    "url": "https://finnhub.io/api/news?id=0a22626ea29ce760ae708c006316bb25dc208e0dac9d2f2f1dc14006ab868855",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753803900,
      "headline": "INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales",
      "id": 136119869,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.",
      "url": "https://finnhub.io/api/news?id=0a22626ea29ce760ae708c006316bb25dc208e0dac9d2f2f1dc14006ab868855"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing",
    "summary": "Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=7e59d70622b5592218bcd72bff17a075183b9d3b0d00021bf9df3b03597e9f63",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753803000,
      "headline": "Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing",
      "id": 136122654,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/829849422/image_829849422.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=7e59d70622b5592218bcd72bff17a075183b9d3b0d00021bf9df3b03597e9f63"
    }
  },
  {
    "ts": null,
    "headline": "Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.",
    "summary": "There is a growing list of challenges to drugs and programs Merck hopes will take up the slack from Keytruda.",
    "url": "https://finnhub.io/api/news?id=2882e025de234379523055e798c0734413f211014488659f7fbc8603b3ac1eda",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753802160,
      "headline": "Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.",
      "id": 136119118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "There is a growing list of challenges to drugs and programs Merck hopes will take up the slack from Keytruda.",
      "url": "https://finnhub.io/api/news?id=2882e025de234379523055e798c0734413f211014488659f7fbc8603b3ac1eda"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk cuts earning forecasts again, names new CEO",
    "summary": "Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its full-year earnings forecasts again as it unveiled a new chief executive to tackle \"recent market challenges\".The lower forecasts came as Novo reported Tuesday an 18 percent sales increase for the first half of the year, while operating profit growth fell to 29 percent after growth of 40 percent in the same period last year.",
    "url": "https://finnhub.io/api/news?id=8b43d9ac684cc22ea214eab1509a7f6a00019b8ddd7ef69b9b6a5ad6e4c2edb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753794404,
      "headline": "Novo Nordisk cuts earning forecasts again, names new CEO",
      "id": 136118163,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its full-year earnings forecasts again as it unveiled a new chief executive to tackle \"recent market challenges\".The lower forecasts came as Novo reported Tuesday an 18 percent sales increase for the first half of the year, while operating profit growth fell to 29 percent after growth of 40 percent in the same period last year.",
      "url": "https://finnhub.io/api/news?id=8b43d9ac684cc22ea214eab1509a7f6a00019b8ddd7ef69b9b6a5ad6e4c2edb3"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares plummet over 20% on weight-loss drug sale slump",
    "summary": "The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.View on euronews",
    "url": "https://finnhub.io/api/news?id=78d08fcbf3acb4ab16fd10f133830318545a9fc0f44229c050cf5870c93b03ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753799066,
      "headline": "Novo Nordisk shares plummet over 20% on weight-loss drug sale slump",
      "id": 136119120,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.View on euronews",
      "url": "https://finnhub.io/api/news?id=78d08fcbf3acb4ab16fd10f133830318545a9fc0f44229c050cf5870c93b03ff"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Dives 20%. Ozempic Maker Unveils New CEO Amid Shock Cut to U.S. Outlook.",
    "summary": "The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and Ozempic in the U.S. market.",
    "url": "https://finnhub.io/api/news?id=e3d8b57bd7a628072f46670b7ddb82c73ab8950ee7e09798039c1ec8d719b1df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753791420,
      "headline": "Novo Nordisk Stock Dives 20%. Ozempic Maker Unveils New CEO Amid Shock Cut to U.S. Outlook.",
      "id": 136118169,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and Ozempic in the U.S. market.",
      "url": "https://finnhub.io/api/news?id=e3d8b57bd7a628072f46670b7ddb82c73ab8950ee7e09798039c1ec8d719b1df"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk plunges as it cuts forecasts again and names new CEO",
    "summary": "STORY: Novo Nordisk shares plunged over a quarter in afternoon trade Tuesday (July 29) before recovering some ground.It happened on the same day it issued a profit warning and announced a new CEO.Investors sold off after the obesity drugmaker cut its full-year sales and operating profit forecasts for the second time this year.Novo now expects sales growth of 8% to 14%  - well down from a previous forecast of between 13% and 21%.It also lowered its operating profit growth estimate.The maker of weight-loss drug Wegovy is struggling to convince investors it can stay competitive in the obesity drug boom against U.S. rival Eli Lilly.Novo said Tuesday its sales rose just under a fifth year-on-year in both the second quarter and first half of the year.The company further added its operating profit also rose by 40% in the April-June quarter.Booming sales of Wegovy turned Novo into Europe's most valuable listed company last year.But its value has since fallen by more than half.Novo has also seen change in the boardroom with CEO Lars Jorgensen pushed out in May.The firm named Maziar Mike Doustdar as its new chief executive Tuesday.Two key aims will be to revive sales and the share price.Novo is due to release full second-quarter earnings on August 6.",
    "url": "https://finnhub.io/api/news?id=27c747c4598814fa3b717424940d6ae74b6d7e0ff8bf795c332bc2eb49176025",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753796859,
      "headline": "Novo Nordisk plunges as it cuts forecasts again and names new CEO",
      "id": 136118158,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Novo Nordisk shares plunged over a quarter in afternoon trade Tuesday (July 29) before recovering some ground.It happened on the same day it issued a profit warning and announced a new CEO.Investors sold off after the obesity drugmaker cut its full-year sales and operating profit forecasts for the second time this year.Novo now expects sales growth of 8% to 14%  - well down from a previous forecast of between 13% and 21%.It also lowered its operating profit growth estimate.The maker of weight-loss drug Wegovy is struggling to convince investors it can stay competitive in the obesity drug boom against U.S. rival Eli Lilly.Novo said Tuesday its sales rose just under a fifth year-on-year in both the second quarter and first half of the year.The company further added its operating profit also rose by 40% in the April-June quarter.Booming sales of Wegovy turned Novo into Europe's most valuable listed company last year.But its value has since fallen by more than half.Novo has also seen change in the boardroom with CEO Lars Jorgensen pushed out in May.The firm named Maziar Mike Doustdar as its new chief executive Tuesday.Two key aims will be to revive sales and the share price.Novo is due to release full second-quarter earnings on August 6.",
      "url": "https://finnhub.io/api/news?id=27c747c4598814fa3b717424940d6ae74b6d7e0ff8bf795c332bc2eb49176025"
    }
  },
  {
    "ts": null,
    "headline": "Instant View: Reaction to new Novo Nordisk CEO, profit warning",
    "summary": "Novo's problems are much deeper than just compunded Wegovy in the U.S. and extend to the international Wegovy franchise and even to Ozempic in diabetes.  \"We are surprised by the appointment of Mike Doustdar as CEO, with feedback suggesting an external candidate may have been preferred.\"",
    "url": "https://finnhub.io/api/news?id=bb9c940dd4d1c9ac09557ae94eecca9a3ec180e237fe52d8a952ff7c3f885b8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753796001,
      "headline": "Instant View: Reaction to new Novo Nordisk CEO, profit warning",
      "id": 136118160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo's problems are much deeper than just compunded Wegovy in the U.S. and extend to the international Wegovy franchise and even to Ozempic in diabetes.  \"We are surprised by the appointment of Mike Doustdar as CEO, with feedback suggesting an external candidate may have been preferred.\"",
      "url": "https://finnhub.io/api/news?id=bb9c940dd4d1c9ac09557ae94eecca9a3ec180e237fe52d8a952ff7c3f885b8f"
    }
  },
  {
    "ts": null,
    "headline": "Here’s What Happened the Last Time Novo Nordisk Stock Was This Oversold",
    "summary": "NVO stock is plunging lower in premarket trading after slashing its guidance for 2025 again.",
    "url": "https://finnhub.io/api/news?id=2366c4733511fbfda545a2c9fd574807af3eafabae85f69da7a9e4812373b260",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753794359,
      "headline": "Here’s What Happened the Last Time Novo Nordisk Stock Was This Oversold",
      "id": 136118164,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO stock is plunging lower in premarket trading after slashing its guidance for 2025 again.",
      "url": "https://finnhub.io/api/news?id=2366c4733511fbfda545a2c9fd574807af3eafabae85f69da7a9e4812373b260"
    }
  },
  {
    "ts": null,
    "headline": "LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases",
    "summary": "REDWOOD CITY, Calif. & SHENZHEN, China, July 29, 2025--LTZ's research collaboration with Lilly advances development of its novel Myeloid Engager Platform, addressing diseases with high unmet need.",
    "url": "https://finnhub.io/api/news?id=004190850b13f61a20f9793334f89b1d47c1a282aed196a0a061213b9a727737",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753794000,
      "headline": "LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases",
      "id": 136119125,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "REDWOOD CITY, Calif. & SHENZHEN, China, July 29, 2025--LTZ's research collaboration with Lilly advances development of its novel Myeloid Engager Platform, addressing diseases with high unmet need.",
      "url": "https://finnhub.io/api/news?id=004190850b13f61a20f9793334f89b1d47c1a282aed196a0a061213b9a727737"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition",
    "summary": "Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its sales and profit estimates.",
    "url": "https://finnhub.io/api/news?id=b10800549a3a52e8fad37dff4ee61a972cce95143a7d0d78d640142131905a08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753792726,
      "headline": "Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition",
      "id": 136118165,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its sales and profit estimates.",
      "url": "https://finnhub.io/api/news?id=b10800549a3a52e8fad37dff4ee61a972cce95143a7d0d78d640142131905a08"
    }
  },
  {
    "ts": null,
    "headline": "Wegovy maker Novo's profit warning triggers $70 billion share rout",
    "summary": "COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesity drug market.  Novo named Maziar Mike Doustdar as its new chief executive, turning to a veteran insider to revive sales and reassure investors rattled by fears the Danish drugmaker is losing ground in the obesity drug race it started.  Doustdar's appointment failed to stem a stock market rout sparked by Novo slashing its outlook for 2025 sales growth to between 8% and 14%, from between 13% and 21% previously.",
    "url": "https://finnhub.io/api/news?id=918ba152273b4eda414a4ba69e832233ba4ae0ea15ad93ab45826cd6098faf5e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753790186,
      "headline": "Wegovy maker Novo's profit warning triggers $70 billion share rout",
      "id": 136119127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesity drug market.  Novo named Maziar Mike Doustdar as its new chief executive, turning to a veteran insider to revive sales and reassure investors rattled by fears the Danish drugmaker is losing ground in the obesity drug race it started.  Doustdar's appointment failed to stem a stock market rout sparked by Novo slashing its outlook for 2025 sales growth to between 8% and 14%, from between 13% and 21% previously.",
      "url": "https://finnhub.io/api/news?id=918ba152273b4eda414a4ba69e832233ba4ae0ea15ad93ab45826cd6098faf5e"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: UnitedHealth Shares Struggle Following Weak 2025 Outlook",
    "summary": "UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted earnings below Street forecasts.",
    "url": "https://finnhub.io/api/news?id=756d723020dae9f74b0f82f62972f7ce86787c5810d92bb3affd39ae16224c95",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753787444,
      "headline": "Wall Street Lunch: UnitedHealth Shares Struggle Following Weak 2025 Outlook",
      "id": 136118531,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442861078/image_1442861078.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted earnings below Street forecasts.",
      "url": "https://finnhub.io/api/news?id=756d723020dae9f74b0f82f62972f7ce86787c5810d92bb3affd39ae16224c95"
    }
  },
  {
    "ts": null,
    "headline": "Obesity drugmaker Novo Nordisk plunges as it cuts forecasts again",
    "summary": "COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for the second time this year, sending its shares down as much as 17%.  The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against U.S. rival Eli Lilly.  \"The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025,\" the company said in a statement.",
    "url": "https://finnhub.io/api/news?id=1055d92d4da8006b869589528cb42ceab4a6a30043702ecb0e12fc4ef1cfb9ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753787252,
      "headline": "Obesity drugmaker Novo Nordisk plunges as it cuts forecasts again",
      "id": 136116954,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for the second time this year, sending its shares down as much as 17%.  The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against U.S. rival Eli Lilly.  \"The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025,\" the company said in a statement.",
      "url": "https://finnhub.io/api/news?id=1055d92d4da8006b869589528cb42ceab4a6a30043702ecb0e12fc4ef1cfb9ae"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This study enrolled patients with treatment-naïve CLL/SLL and those who had been previously treated but were BTK inhibitor-naïve. The stu",
    "url": "https://finnhub.io/api/news?id=0f3c9c0ae1207d3396ca46bf2277c872595d3a90b56f3a47c2a9041d31f27342",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753785900,
      "headline": "Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL",
      "id": 136116955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This study enrolled patients with treatment-naïve CLL/SLL and those who had been previously treated but were BTK inhibitor-naïve. The stu",
      "url": "https://finnhub.io/api/news?id=0f3c9c0ae1207d3396ca46bf2277c872595d3a90b56f3a47c2a9041d31f27342"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Set to Gain on Early Alzheimer’s Trial Results, Says BMO Capital",
    "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the stocks to benefit from an onshoring boom. On July 22, BMO Capital reaffirmed its $900 price target and Outperform rating for Eli Lilly & Company (NYSE:LLY). According to the investment firm, an interim analysis of Eli Lilly’s TRAILBLAZER-ALZ 3 presymptomatic Alzheimer’s trial may be done before the […]",
    "url": "https://finnhub.io/api/news?id=92622eecbae3a6ebdf6409aa75072c733f454112859969c3f519d0b95fa8fcc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753767437,
      "headline": "Eli Lilly (LLY) Stock Set to Gain on Early Alzheimer’s Trial Results, Says BMO Capital",
      "id": 136113386,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the stocks to benefit from an onshoring boom. On July 22, BMO Capital reaffirmed its $900 price target and Outperform rating for Eli Lilly & Company (NYSE:LLY). According to the investment firm, an interim analysis of Eli Lilly’s TRAILBLAZER-ALZ 3 presymptomatic Alzheimer’s trial may be done before the […]",
      "url": "https://finnhub.io/api/news?id=92622eecbae3a6ebdf6409aa75072c733f454112859969c3f519d0b95fa8fcc7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Announces New Phase 3 Trial Results for Orforglipron",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company (NYSE:LLY) announced new Phase 3 trial results for Orforglipron, which is an oral drug for adults with type 2 diabetes. This comes as a breakthrough for the company as Orforglipron is the first […]",
    "url": "https://finnhub.io/api/news?id=c2d7d45bac0e4bd2b892174ff3af985c35b332efccf93dc8472bb087fdc310c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753766979,
      "headline": "Eli Lilly and Company (LLY) Announces New Phase 3 Trial Results for Orforglipron",
      "id": 136113387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company (NYSE:LLY) announced new Phase 3 trial results for Orforglipron, which is an oral drug for adults with type 2 diabetes. This comes as a breakthrough for the company as Orforglipron is the first […]",
      "url": "https://finnhub.io/api/news?id=c2d7d45bac0e4bd2b892174ff3af985c35b332efccf93dc8472bb087fdc310c9"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Pfizer: “We are Still on the Verge of Finding Out What the Seagen Acquisition Does”",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks that Jim Cramer weighed in on. A caller asked if they should continue to hold the stock or sell it. In response, Cramer stated: “I can’t ask you to do that because we are still on the verge of finding out what the Seagen acquisition does. Let’s […]",
    "url": "https://finnhub.io/api/news?id=bba0c8322169d354065d68dff88d56b2f61b58222625a9e7285dbd98e802c730",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753766916,
      "headline": "Jim Cramer on Pfizer: “We are Still on the Verge of Finding Out What the Seagen Acquisition Does”",
      "id": 136113388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks that Jim Cramer weighed in on. A caller asked if they should continue to hold the stock or sell it. In response, Cramer stated: “I can’t ask you to do that because we are still on the verge of finding out what the Seagen acquisition does. Let’s […]",
      "url": "https://finnhub.io/api/news?id=bba0c8322169d354065d68dff88d56b2f61b58222625a9e7285dbd98e802c730"
    }
  },
  {
    "ts": null,
    "headline": "RiverPark Long/Short Opportunity Fund Q2 2025 Investor Letter",
    "summary": "RiverPark Long/Short Opportunity Fund Q2 2025 Investor Letter",
    "url": "https://finnhub.io/api/news?id=5a6f5e3026ad9824cb355e784dc283acb18353968e69c8324075032074e7663e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753755000,
      "headline": "RiverPark Long/Short Opportunity Fund Q2 2025 Investor Letter",
      "id": 136114050,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5a6f5e3026ad9824cb355e784dc283acb18353968e69c8324075032074e7663e"
    }
  },
  {
    "ts": null,
    "headline": "BME: The Resilient Income Investment Of The Healthcare Industry",
    "summary": "BlackRock Health Sciences Trust offers a resilient 8.63% dividend yield, low expense ratio, and conservative, low-risk positioning. See more on BME ETF here.",
    "url": "https://finnhub.io/api/news?id=78240d01203e7108640de3e61a12e015ad3c84d30c01e10965bf01bcf0b6bbe0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753747321,
      "headline": "BME: The Resilient Income Investment Of The Healthcare Industry",
      "id": 136112843,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635084121/image_1635084121.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Trust offers a resilient 8.63% dividend yield, low expense ratio, and conservative, low-risk positioning. See more on BME ETF here.",
      "url": "https://finnhub.io/api/news?id=78240d01203e7108640de3e61a12e015ad3c84d30c01e10965bf01bcf0b6bbe0"
    }
  }
]